Touchscreen-compatible, real-time electrochemical sensing of SARS-CoV-2
- Funded by National Institutes of Health (NIH)
- Total publications:0 publications
Grant number: 4U01AA029316-02
Grant search
Key facts
Disease
COVID-19Start & end year
20202023Known Financial Commitments (USD)
$455,938Funder
National Institutes of Health (NIH)Principal Investigator
PROFESSOR Suzie PunResearch Location
United States of AmericaLead Research Institution
UNIVERSITY OF WASHINGTONResearch Priority Alignment
N/A
Research Category
Pathogen: natural history, transmission and diagnostics
Research Subcategory
Diagnostics
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Not applicable
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified
Abstract
PROJECT SUMMARY The SARS-CoV-2 coronavirus, the cause of the COVID-19 global pandemic, is efficiently spread and has reached over 27 million confirmed cases as of September 8, 2020. There is therefore an urgent need for new technologies that can provide early detection of virus, reducing the transmission and infection rate. The goal of this proposal is to develop an integrated biosensor- touchscreen that sensitivity reports surface contact with SARS-CoV-2. In our preliminary work, we have identified several aptamers that bind specifically to the envelope-anchored trimeric spike (S) protein of SARS-CoV-2, but not of SARS-CoV or MERS. In comparison to antibodies, aptamers are synthetic molecules that more thermally stable and lower cost while providing similar specificity and affinity of target binding. In this application, we propose to integrate aptamer-based biosensing of SARS-CoV-2 into a touchscreen device. Our main objectives are to 1) engineer conformation switching aptamers for electrochemical sensing of SARS-CoV-2 binding, 2) develop nanogap capacitive sensors as a uniquely complementary approach to capacitive touchscreen technology and 3) build and test an integrated biosensor and touchscreen array that can detect SARS-CoV-2 from patient samples. Successful completion of these aims will result in a novel automatic sensing platform for SARS-CoV-2. This technology could transform personal device touchscreens as well as to multi-user touchscreen devices in hospitals, airports, libraries, restaurants, for early detection, curbing transmission rates from secondary exposure. Importantly, the developed technology could be adapted for other electronic sensing platforms, and easily applied for future pathogen detection.